Terns Pharmaceuticals (NASDAQ:TERN) Receives Market Perform Rating from Citizens Jmp

Citizens Jmp reiterated their market perform rating on shares of Terns Pharmaceuticals (NASDAQ:TERN) in a report released on Thursday,Benzinga reports.

TERN has been the subject of a number of other research reports. HC Wainwright restated a “neutral” rating and issued a $53.00 price target on shares of Terns Pharmaceuticals in a research note on Wednesday. UBS Group upgraded shares of Terns Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, December 4th. Oppenheimer raised their price objective on shares of Terns Pharmaceuticals from $28.00 to $58.00 and gave the stock an “outperform” rating in a report on Tuesday, December 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of Terns Pharmaceuticals in a research report on Monday, December 29th. Finally, TD Cowen upgraded shares of Terns Pharmaceuticals to a “strong-buy” rating in a research note on Friday, February 20th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $56.90.

Terns Pharmaceuticals Stock Up 0.6%

Shares of TERN opened at $53.17 on Thursday. The business’s 50 day moving average is $40.96 and its two-hundred day moving average is $28.74. Terns Pharmaceuticals has a 52-week low of $1.87 and a 52-week high of $53.19. The firm has a market cap of $5.52 billion, a price-to-earnings ratio of -51.62 and a beta of -0.31.

Insider Activity at Terns Pharmaceuticals

In other Terns Pharmaceuticals news, CEO Amy L. Burroughs sold 14,583 shares of the business’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $46.71, for a total transaction of $681,171.93. Following the completion of the sale, the chief executive officer owned 288,976 shares in the company, valued at $13,498,068.96. The trade was a 4.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Emil Kuriakose sold 1,155 shares of the stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $38.57, for a total transaction of $44,548.35. Following the sale, the insider directly owned 50,365 shares in the company, valued at $1,942,578.05. This trade represents a 2.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 170,409 shares of company stock worth $6,563,769. Corporate insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Terns Pharmaceuticals in the 4th quarter valued at about $25,000. GAMMA Investing LLC raised its stake in Terns Pharmaceuticals by 762.4% during the fourth quarter. GAMMA Investing LLC now owns 871 shares of the company’s stock worth $35,000 after acquiring an additional 770 shares during the period. Engineers Gate Manager LP acquired a new stake in Terns Pharmaceuticals during the second quarter worth about $41,000. iA Global Asset Management Inc. bought a new position in Terns Pharmaceuticals in the fourth quarter worth about $43,000. Finally, Canada Pension Plan Investment Board acquired a new position in Terns Pharmaceuticals in the second quarter valued at approximately $46,000. 98.26% of the stock is currently owned by institutional investors.

Key Terns Pharmaceuticals News

Here are the key news stories impacting Terns Pharmaceuticals this week:

• Positive Sentiment: Merck agreed to buy Terns for $53.00 per share in cash, valuing the company at about $6.7 billion — investors view this as a strong exit valuation and strategic validation of Terns’ lead hematology asset, TERN‑701. Merck to Acquire Terns — Business Wire
• Positive Sentiment: Market reaction: shares traded with far above‑average volume and hit a new 52‑week high as the deal priced a near‑term valuation floor for shareholders. Terns Hits New 52‑Week High — American Banking News
• Neutral Sentiment: Deal mechanics and timing — Merck’s agreement is structured as a tender offer subject to customary conditions and shareholder participation; closing was guided for Q2 2026, so completion risk and timeline remain relevant. Merck Buyout Coverage — Reuters
• Neutral Sentiment: Analyst posture unchanged around the deal: several firms (HC Wainwright, TD Cowen, Citizens/JMP) reaffirmed neutral/hold ratings or price targets very close to the $53 offer price, implying limited upside beyond the bid while the transaction is pending. Analyst Notes & Ratings — MarketBeat
• Negative Sentiment: Litigation/investigations: multiple shareholder law firms have launched probes into whether the $53 per‑share price and sale process were fair — these challenges could delay closing, increase transaction costs, or pressure the timeline. Investor Alert — Kahn Swick & Foti (Business Wire)

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.